Literature DB >> 11430939

Efficacy of 7-day treatment with metronidazole+miconazole (Neo-Penotran) - a triple-active pessary for the treatment of single and mixed vaginal infections.

E Ozyurt1, M B Toykuliyeva, I L Danilyans, O Morton, G Baktir.   

Abstract

OBJECTIVE: To evaluate the efficacy of Neo-Penotran pessaries (metronidazole 500 mg + miconazole nitrate 100 mg) in candidal, bacterial and trichomonal vaginitis and in mixed vaginal infections.
METHOD: Ninety-seven patients with clinical diagnosis of vaginitis entered this open, non-comparative study. Each patient inserted one pessary twice daily for 7 days. Gynecological and microbiological assessments were carried out before, and 8-10/21-23 days after the start of treatment.
RESULTS: Vaginitis symptoms were resolved in 91% of the 74 patients evaluated, and improved in a further 7%. Microbiological cure rates were 97.3% for trichomonal, 86.6% for bacterial and 81% for candidal vaginitis. Recurrence rates were 2.7, 3.8 and 16.1%, respectively. Overall microbiological cure rate for mixed infections was 86%, with 93% for trichomonal+bacterial, and 73% for bacterial+candidal vaginitis. In two out of three cases with trichomonal+bacterial+candidal infection, the microorganisms were eradicated completely.
CONCLUSION: Neo-Penotran provides immediate and effective treatment for vaginitis, irrespective of single or multiple infection, even when the diagnosis may be uncertain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11430939     DOI: 10.1016/s0020-7292(01)00388-5

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  6 in total

1.  Mode of action and safety of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050.

Authors:  S Riazi; S E Dover; M L Chikindas
Journal:  J Appl Microbiol       Date:  2012-07-24       Impact factor: 3.772

2.  Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis.

Authors:  Milce Costa; Xisto Sena Passos; André Thiago Borges Miranda; Rosane Silva Carneiro de Araújo; Claudete Rodrigues Paula; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2004-01       Impact factor: 2.574

3.  Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses.

Authors:  Jack D Sobel; Navkiranjot Kaur; Nicole A Woznicki; Dina Boikov; Tina Aguin; Gurveer Gill; Robert A Akins
Journal:  Infect Drug Resist       Date:  2019-07-24       Impact factor: 4.003

4.  Spermicidal activity of the safe natural antimicrobial peptide subtilosin.

Authors:  Katia E Sutyak; Robert A Anderson; Sara E Dover; Kenneth A Feathergill; Alla A Aroutcheva; Sebastian Faro; Michael L Chikindas
Journal:  Infect Dis Obstet Gynecol       Date:  2008-10-09

5.  Safety study of an antimicrobial peptide lactocin 160, produced by the vaginal Lactobacillus rhamnosus.

Authors:  Sara E Dover; Alla A Aroutcheva; S Faro; Michael L Chikindas
Journal:  Infect Dis Obstet Gynecol       Date:  2007

6.  Aerobic Vaginitis Diagnosis Criteria Combining Gram Stain with Clinical Features: An Establishment and Prospective Validation Study.

Authors:  Mengting Dong; Chen Wang; Huiyang Li; Ye Yan; Xiaotong Ma; Huanrong Li; Xingshuo Li; Huihui Wang; Yixuan Zhang; Wenhui Qi; Ke Meng; Wenyan Tian; Yingmei Wang; Aiping Fan; Cha Han; Gilbert G G Donders; Fengxia Xue
Journal:  Diagnostics (Basel)       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.